These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 16337379)

  • 1. Identification of phosphodiesterase-1 and 5 dual inhibitors by a ligand-based virtual screening optimized for lead evolution.
    Yamazaki K; Kusunose N; Fujita K; Sato H; Asano S; Dan A; Kanaoka M
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1371-9. PubMed ID: 16337379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of hydroxamic acid analogs as dual inhibitors of phosphodiesterase-1 and -5.
    Dan A; Shiyama T; Yamazaki K; Kusunose N; Fujita K; Sato H; Matsui K; Kitano M
    Bioorg Med Chem Lett; 2005 Sep; 15(18):4085-90. PubMed ID: 16005625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example.
    Castro A; Jerez MJ; Gil C; Calderón F; Doménech T; Nueda A; Martínez A
    Eur J Med Chem; 2008 Jul; 43(7):1349-59. PubMed ID: 18082290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.
    Chappie TA; Humphrey JM; Allen MP; Estep KG; Fox CB; Lebel LA; Liras S; Marr ES; Menniti FS; Pandit J; Schmidt CJ; Tu M; Williams RD; Yang FV
    J Med Chem; 2007 Jan; 50(2):182-5. PubMed ID: 17228859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel benzimidazole derivatives as phosphodiesterase 10A (PDE10A) inhibitors with improved metabolic stability.
    Chino A; Masuda N; Amano Y; Honbou K; Mihara T; Yamazaki M; Tomishima M
    Bioorg Med Chem; 2014 Jul; 22(13):3515-26. PubMed ID: 24837154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for generating less toxic P-selectin inhibitors: pharmacophore modeling, virtual screening and counter pharmacophore screening to remove toxic hits.
    Ananthula RS; Ravikumar M; Pramod AB; Madala KK; Mahmood SK
    J Mol Graph Model; 2008 Nov; 27(4):546-57. PubMed ID: 18993099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective PDE5 inhibitors.
    Feixas J; Giovannoni MP; Vergelli C; Gavaldà A; Cesari N; Graziano A; Dal Piaz V
    Bioorg Med Chem Lett; 2005 May; 15(9):2381-4. PubMed ID: 15837329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
    Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
    Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A discussion of measures of enrichment in virtual screening: comparing the information content of descriptors with increasing levels of sophistication.
    Bender A; Glen RC
    J Chem Inf Model; 2005; 45(5):1369-75. PubMed ID: 16180913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and Optimization of a Series of Pyrimidine-Based Phosphodiesterase 10A (PDE10A) Inhibitors through Fragment Screening, Structure-Based Design, and Parallel Synthesis.
    Shipe WD; Sharik SS; Barrow JC; McGaughey GB; Theberge CR; Uslaner JM; Yan Y; Renger JJ; Smith SM; Coleman PJ; Cox CD
    J Med Chem; 2015 Oct; 58(19):7888-94. PubMed ID: 26378882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond the virtual screening paradigm: structure-based searching for new lead compounds.
    Schlosser J; Rarey M
    J Chem Inf Model; 2009 Apr; 49(4):800-9. PubMed ID: 19354328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin.
    Durgam GG; Virag T; Walker MD; Tsukahara R; Yasuda S; Liliom K; van Meeteren LA; Moolenaar WH; Wilke N; Siess W; Tigyi G; Miller DD
    J Med Chem; 2005 Jul; 48(15):4919-30. PubMed ID: 16033271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of novel benzimidazole derivatives as phosphodiesterase 10A inhibitors with reduced CYP1A2 inhibition.
    Hamaguchi W; Masuda N; Isomura M; Miyamoto S; Kikuchi S; Amano Y; Honbou K; Mihara T; Watanabe T
    Bioorg Med Chem; 2013 Dec; 21(24):7612-23. PubMed ID: 24238902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 4-hydroxy-1,6-naphthyridine-3-carbonitrile derivatives as novel PDE10A inhibitors.
    Bauer U; Giordanetto F; Bauer M; O'Mahony G; Johansson KE; Knecht W; Hartleib-Geschwindner J; Carlsson ET; Enroth C
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1944-8. PubMed ID: 22321214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors.
    Kehler J; Ritzen A; Langgård M; Petersen SL; Farah MM; Bundgaard C; Christoffersen CT; Nielsen J; Kilburn JP
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3738-42. PubMed ID: 21602043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating virtual screening in lead discovery.
    Oprea TI; Matter H
    Curr Opin Chem Biol; 2004 Aug; 8(4):349-58. PubMed ID: 15288243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benzothiophene derivatives as phosphodiesterase 10A (PDE10A) inhibitors: Hit-to-lead studies.
    Kawamoto Y; Tomino M; Hiramatsu K; Oyama Y; Hayashi Y
    Bioorg Med Chem Lett; 2019 Jun; 29(11):1419-1422. PubMed ID: 30952590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel triazines as potent and selective phosphodiesterase 10A inhibitors.
    Malamas MS; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Hage T; Ni Y; Erdei J; Fan KY; Parris K; Marquis KL; Grauer S; Brennan J; Navarra R; Graf R; Harrison BL; Robichaud A; Kronbach T; Pangalos MN; Brandon NJ; Hoefgen N
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5876-84. PubMed ID: 22902656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment.
    Chen Y; Li H; Tang W; Zhu C; Jiang Y; Zou J; Yu Q; You Q
    Eur J Med Chem; 2009 Jul; 44(7):2868-76. PubMed ID: 19136179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based pharmacophore design and virtual screening for novel angiotensin converting enzyme 2 inhibitors.
    Rella M; Rushworth CA; Guy JL; Turner AJ; Langer T; Jackson RM
    J Chem Inf Model; 2006; 46(2):708-16. PubMed ID: 16563001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.